236 related articles for article (PubMed ID: 35110501)
1. TGF-β and Cancer Immunotherapy.
MaruYama T; Chen W; Shibata H
Biol Pharm Bull; 2022; 45(2):155-161. PubMed ID: 35110501
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta: a master immune regulator.
Larson C; Oronsky B; Carter CA; Oronsky A; Knox SJ; Sher D; Reid TR
Expert Opin Ther Targets; 2020 May; 24(5):427-438. PubMed ID: 32228232
[No Abstract] [Full Text] [Related]
3. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.
Karami Z; Mortezaee K; Majidpoor J
Int Immunopharmacol; 2023 Sep; 122():110648. PubMed ID: 37459782
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-β signaling: Tumorigenesis and targeting for cancer therapy.
Ahmadi A; Najafi M; Farhood B; Mortezaee K
J Cell Physiol; 2019 Aug; 234(8):12173-12187. PubMed ID: 30537043
[TBL] [Abstract][Full Text] [Related]
5. Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells.
Shi H; Yang Y
Cancer Med; 2021 Jun; 10(11):3794-3807. PubMed ID: 33932112
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors win the 2018 Nobel Prize.
Huang PW; Chang JW
Biomed J; 2019 Oct; 42(5):299-306. PubMed ID: 31783990
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Zhang L; Yu Z; Muranski P; Palmer DC; Restifo NP; Rosenberg SA; Morgan RA
Gene Ther; 2013 May; 20(5):575-80. PubMed ID: 22972494
[TBL] [Abstract][Full Text] [Related]
8. Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren H
Expert Opin Ther Targets; 2019 Aug; 23(8):679-693. PubMed ID: 31232607
[No Abstract] [Full Text] [Related]
9. The Love-Hate Relationship Between TGF-β Signaling and the Immune System During Development and Tumorigenesis.
Chen B; Mu C; Zhang Z; He X; Liu X
Front Immunol; 2022; 13():891268. PubMed ID: 35720407
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.
Yang L; Pang Y; Moses HL
Trends Immunol; 2010 Jun; 31(6):220-7. PubMed ID: 20538542
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
Bialkowski L; Van der Jeught K; Bevers S; Tjok Joe P; Renmans D; Heirman C; Aerts JL; Thielemans K
Int J Cancer; 2018 Aug; 143(3):686-698. PubMed ID: 29464699
[TBL] [Abstract][Full Text] [Related]
12. Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy.
Zhao H; Wei J; Sun J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107101. PubMed ID: 33099067
[TBL] [Abstract][Full Text] [Related]
13. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.
Yi M; Li T; Niu M; Wu Y; Zhao Z; Wu K
Front Immunol; 2022; 13():1061394. PubMed ID: 36601124
[TBL] [Abstract][Full Text] [Related]
14. Transforming Growth Factor-β Signaling in Immunity and Cancer.
Batlle E; Massagué J
Immunity; 2019 Apr; 50(4):924-940. PubMed ID: 30995507
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.
van den Bulk J; de Miranda NFCC; Ten Dijke P
Clin Sci (Lond); 2021 Jan; 135(1):35-52. PubMed ID: 33399850
[TBL] [Abstract][Full Text] [Related]
16. Transforming Growth Factor-β1 in Cancer Immunology: Opportunities for Immunotherapy.
Villar VH; Subotički T; Đikić D; Mitrović-Ajtić O; Simon F; Santibanez JF
Adv Exp Med Biol; 2023; 1408():309-328. PubMed ID: 37093435
[TBL] [Abstract][Full Text] [Related]
17. MicroRNAs, TGF-β signaling, and the inflammatory microenvironment in cancer.
Guo L; Zhang Y; Zhang L; Huang F; Li J; Wang S
Tumour Biol; 2016 Jan; 37(1):115-25. PubMed ID: 26563372
[TBL] [Abstract][Full Text] [Related]
18. TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.
Huang CH; Liao YJ; Chiou TJ; Huang HT; Lin YH; Twu YC
Immunobiology; 2019 Sep; 224(5):649-658. PubMed ID: 31421859
[TBL] [Abstract][Full Text] [Related]
19. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
20. Quantitative modeling and analysis of the transforming growth factor beta signaling pathway.
Chung SW; Miles FL; Sikes RA; Cooper CR; Farach-Carson MC; Ogunnaike BA
Biophys J; 2009 Mar; 96(5):1733-50. PubMed ID: 19254534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
